GlassScriptPhysician profile
Vikas V Desai
NPI 1922069012
$1,976.08
in general payments reported to CMS, 2019-2025
29 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.96 · 2020: $217 · 2021: $107 · 2022: $530 · 2023: $508 · 2024: $420 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.28 | 2021-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $290.86 | 2022-2023 | |
| Abbvie INC. | $172.20 | 2021-2025 | |
| Medtronic Vascular, INC. | $143.77 | 2020 | |
| Novo Nordisk INC | $132.23 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $93.72 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $73.49 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $72.58 | 2020-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $62.54 | 2022-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.20 | 2024-2025 | |
| Pfizer INC. | $45.28 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $40.99 | 2020-2024 | Breztri, Airsupra |
| Medtronic, INC. | $39.81 | 2024 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $34.68 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $29.37 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $28.86 | 2024 | Korlym |
| Neuronetics, INC. | $25.99 | 2019 | |
| Medtronic USA, INC. | $22.91 | 2019 | |
| Astellas Pharma US INC | $22.85 | 2023 | Veozah |
| Shield Therapeutics INC | $22.02 | 2024 | |
| Renalytix Ai, INC. | $21.23 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Intra-Sana Laboratories | $20.47 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Hikma Pharmaceuticals USA | $19.66 | 2023 | Ryaltris, Mitigare |
| Esperion Therapeutics, INC. | $18.00 | 2020 | |
| Abbott Laboratories | $17.53 | 2021 | |
| Hologic Sales and Service, LLC | $16.03 | 2025 | Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $13.56 | 2025 | Voquezna |
| Allergan, INC. | $12.80 | 2020 | |
| Sanofi Pasteur INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.